New hope for Tough-to-Treat colon cancer?

NCT ID NCT05513742

Completed Disease control Sponsor: Compass Therapeutics Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 29, 2026 · Updated 2 times

Summary

This study tested an experimental drug called CTX-009 in 49 adults with metastatic colorectal cancer that had worsened after two or three prior treatments. The goal was to see if the drug could shrink tumors or stop them from growing. Results will help determine if further testing is warranted.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for COLON CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

colon carcinoma colonic neoplasm colorectal cancer colorectal neoplasm rectal cancer rectal neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

COLON CANCER METASTATIC COLORECTAL CANCER RECTAL CANCER

Contacts and locations

Locations

Florida Cancer Specialists & Research Institute - North

St. Petersburg, Florida, 33705, United States
Florida Cancer Specialists & Research Institute - South

Fort Myers, Florida, 33916, United States
Genesis Cancer and Blood Institute

Hot Springs, Arkansas, 71913, United States
Mary Crowley Cancer Research

Dallas, Texas, 75230, United States
Rutgers Cancer Institute of New Jersey

New Brunswick, New Jersey, 08903, United States
SCRI Oncology Partners

Nashville, Tennessee, 37203, United States
Zangmeister Cancer Center

Columbus, Ohio, 43219, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.